Patent ID: 8569274

Claim:
A method of treating excessive uterine bleeding resulting from a coagulation disorder comprising administering a therapeutically effective amount of a progesterone antagonist, a selective progesterone receptor modulator (SPRM), or an active metabolite thereof, or a combination of two or more of said progesterone antagonists, SPRMs, or active metabolites, or a combination of two or more of said progesterone antagonists, SPRMs or active metabolites thereof, to a woman in need thereof, wherein said progesterone antagonist or SPRM is selected from the group consisting of CDB-2914, mifepristone, asoprisnil, CDB-4124, onapristone, org33628, tanaproget, tanaproget-combo, 11 beta-((4-N,N-dimethylamino)-phenyl)-17 beta-hydroxy-18-methyl-17 alpha-propinyl-4,9(10)-estradien-3-one, 11 beta-((4-N,N-dimethylamino)-phenyl)-17 a beta-hydroxy-17a alpha-propinyl-D-homo-4,9(10),16-estradien-3-one, 11 beta-4-methoxyphenyl-17 beta-hydroxy-17 alpha-ethinyl-4,9(10)-estradien-3-one, 11 beta-(4-acetylphenyl)-17 beta-hydroxy-17 alpha-(prop-1-inyl)-4,9(10)estradien-3-one, 11 beta-(4-dimethylaminophenyl)-17 alpha-hydroxy-17 beta-(3-hydroxy-propyl)-13 alpha-methyl-4,9-gonadien-3-one, (Z)-11 beta-[4-(dimethylamino)phenyl]-17beta-hydroxy-17alpha-(3-hydroxy-1-propenyl)-estr-4-en-3-one-5, 11 beta-(4-acetylphenyl)-17 beta-hydroxy-17 alpha-(3-hydroxyprop-1-(Z)-enyl)-4,9(10)-estradien-3-one, 11 beta-(4-cyanophenyl)-17 beta-hydroxy-17 alpha-(3-hydroxyprop-1-(Z)-enyl)-4-androsten-3-one, 11 beta, 19-(4-(3-pyridinyl)-o-phenylene)-17 beta-hydroxy-17 alpha-(3-hydroxyprop-1-(Z)-enyl)-4-androsten-3-one, and an active metabolite of any of said progesterone antagonists or SPRMs.